Integra LifeSciences (IART) Institutional Ownership

84.78% of Integra LifeSciences' stock is owned by institutional investors. Learn more on IART's institutional investor holdings.

Of the 181 institutional investors that purchased Integra LifeSciences' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Rubric Capital Management LP ($3.40M), Paradigm Capital Management Inc. NY ($3.18M), Sachem Head Capital Management LP ($2.43M), Assenagon Asset Management S.A. ($1.90M), Soleus Capital Management L.P. ($1.59M), Systematic Financial Management LP ($1.04M), and Access Investment Management LLC ($898.67K).

Institutional investors have bought a total of 15,160,902 shares in the last 24 months. This purchase volume represents approximately $182.80M in transactions.

Of the 81 institutional investors that sold Integra LifeSciences' stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Deerfield Management Company L.P. ($174.36M), Invesco Ltd. ($50.22M), JPMorgan Chase & Co. ($14.53M), Millennium Management LLC ($5.69M), UBS Group AG ($4.71M), Assenagon Asset Management S.A. ($1.45M), and American Century Companies Inc. ($631.57K).

Institutional investors have sold a total of 256,579,765 shares in the last 24 months. This volume of shares sold represents approximately $3.66B in transactions.